Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Nederlands Tijdschrift Voor Geneeskunde|February 12, 2025
[Handling fear of cancer recurrence]Chris Hinnen, Aart Beeker, Justine Kuiper, et al.
International Journal of Clinical Oncology|March 1, 2008
Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinomaAart Beeker, Epie Boven, Pierre Lefesvre, et al.
Cancer Reports (Hoboken, N.J.)|June 19, 2021
Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapyEvert S M van Aken, Aart Beeker, Ilse Houtenbos, et al.
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|April 15, 2023
Prevalence and treatment of anemia and secondary iron overload in patients with a myelodysplastic syndrome: Real-world data from a multicenter cohort studyCamiel L M de Roij van Zuijdewijn, Peter E Westerweel, Martin R Schipperus, et al.
The Lancet. Oncology|June 13, 2015
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trialSil Kordes, Michael N Pollak, Aeilko H Zwinderman, et al.
Journal of Geriatric Oncology|June 16, 2015
Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC studyJudith R Kroep, Erik van Werkhoven, Marco Polee, et al.
Frontiers in Pharmacology|October 7, 2016
Adherence and Patients' Experiences with the Use of Capecitabine in Daily PracticeLonneke Timmers, Christel C L M Boons, Dirk Mangnus, et al.
BMC Palliative Care|August 29, 2014
Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexoneElisabeth Cw Neefjes, Maurice Jdl van der Vorst, Manon Sa Boddaert, et al.
European Journal of Haematology|July 13, 2019
Treatment strategies for polycythemia vera: Observations in a Dutch "real-world" cohort studyClaire van de Ree-Pellikaan, Arne de Kreuk, Cees G Schaar, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2017
A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trialEsther W Bouman-Wammes, H Pieter van den Berg, Linda de Munck, et al.
Pageof 5